We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Caliper Life Sciences Closes Multiple LabChip and IVIS Sales at Top Pharma and Biotech Companies
News

Caliper Life Sciences Closes Multiple LabChip and IVIS Sales at Top Pharma and Biotech Companies

Caliper Life Sciences Closes Multiple LabChip and IVIS Sales at Top Pharma and Biotech Companies
News

Caliper Life Sciences Closes Multiple LabChip and IVIS Sales at Top Pharma and Biotech Companies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Caliper Life Sciences Closes Multiple LabChip and IVIS Sales at Top Pharma and Biotech Companies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Caliper Life Sciences, Inc. announced expanded sales of its LabChip and IVIS drug discovery and development systems to top-tier customers including PfizerAstraZeneca, and Momenta Pharmaceuticals.

These systems will help scientists to accelerate and improve drug discovery and development.

Caliper's LabChip and IVIS systems are designed to connect research data from in vitro experimentation to in vivo experimentation. By connecting in vivo and in vitro experimentation, researchers are able to predict human outcomes and reduce drug candidate attrition.

Caliper's portfolio of offerings provides the pharmaceutical industry with the technology and support to improve clinical relevance and develop effective treatments for disease.

"With the Caliper name supporting the IVIS imaging system, we are seeing rapid adoption in the commercial sector," said Kevin Hrusovsky, CEO of Caliper Life Sciences.

“The sales of both products are representative of Caliper's ability to meet the needs and demands of the industry while fostering the company's own growth and strategic direction as a leading provider of in vitro and in vivo drug discovery and development technologies."

Advertisement